BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 3.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,081,316 shares of the biotechnology company's stock after selling 82,427 shares during the period. Rice Hall James & Associates LLC owned about 1.00% of BioCryst Pharmaceuticals worth $15,651,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BCRX. Fisher Asset Management LLC boosted its holdings in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock valued at $25,369,000 after purchasing an additional 481,359 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of BioCryst Pharmaceuticals by 472.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company's stock valued at $3,776,000 after purchasing an additional 409,938 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after buying an additional 375,890 shares during the last quarter. Cinctive Capital Management LP purchased a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $2,082,000. Finally, Two Sigma Advisers LP grew its position in shares of BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock worth $16,576,000 after buying an additional 261,500 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock traded down $0.01 during trading hours on Thursday, reaching $9.39. The stock had a trading volume of 3,036,200 shares, compared to its average volume of 2,801,047. The firm has a 50-day simple moving average of $7.94 and a 200-day simple moving average of $7.81. The firm has a market capitalization of $1.94 billion, a PE ratio of -15.38 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Needham & Company LLC upped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a report on Monday, January 13th. JMP Securities restated a "market outperform" rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Evercore ISI lifted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Royal Bank of Canada restated an "outperform" rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays lifted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.